CONTACT

+91 80 2808 2808

info@biocon.com

Company Statements 2019

Biocon / News – Posts / Company Statements / Company Statements 2019

U.S. FDA Completes Pre-Approval Inspection of Two New Biocon Biologics Facilities in Bengaluru

Fri, 20-Sep-2019
Posted by: BIOCON

U.S. FDA Issues Complete Response Letter for New Drug Application for Insulin Glargine; Commercialization Plans Remain Unchanged

Sat, 31-Aug-2019
Posted by: BIOCON

U.S. FDA completes surveillance (routine) cGMP inspection of one of our Biologics Drug Product facilities in Bengaluru

Sat, 31-Aug-2019
Posted by: BIOCON

Pre-Approval U.S. FDA Inspection Conducted at Biocon’s Insulins Facilities in Malaysia

Mon, 08-Jul-2019
Posted by: BIOCON

Biocon Biologics Facilities in Bengaluru Receive EU GMP Certification

Fri, 14-Jun-2019
Posted by: BIOCON

Biocon Retains Economic Interest in Global Commercialization of Hulio®, (biosimilar Adalimumab) in-licensed by Mylan

Tue, 07-May-2019
Posted by: BIOCON

Biocon Facility Completes Pre Approval U.S. FDA Inspection

Wed, 06-Mar-2019
Posted by: BIOCON

Biocon Facilities complete Pre Approval U.S. FDA lnspection

Mon, 18-Feb-2019
Posted by: BIOCON